Pramlintide and the treatment of diabetes: a review of the data since its introduction

Bibliography

• The DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405
   PubMed Web of Science ®Google Scholar
• Sorkin JD, Muller DC, Fleg JL, Andres R. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 2005;28:2626-32
   PubMed Web of Science ®Google Scholar
• Cavalot F, Petrelli A, Traversa M, Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006;91:813-19
   PubMed Web of Science ®Google Scholar
• Beckman JA, Goldfine AB, Gordon MB, Creager MA. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 2001;103:1618-23
   PubMed Web of Science ®Google Scholar
• Williams SB, Goldfine AB, Timimi FK. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998;97:1695-701
   PubMed Web of Science ®Google Scholar
• Shimabukuro M, Higa N, Chinen I, Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 2006;91:837-42
   PubMed Web of Science ®Google Scholar
• Monnier L, Mas E, Ginet C, Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-7
   PubMed Web of Science ®Google Scholar
• Esposito K, Nappo F, Marfella R, Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002;106:2067-72
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R, for the STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-94
   PubMed Web of Science ®Google Scholar
• Esposito K, Giugliano D, Nappo F, Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004;110:214-19
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Chiasson JL, Koehler C, Acarbose slows progression of intima-media thickness of carotid arteries in subjects with impaired glucose tolerance. Stroke 2004;35:1073-8
   PubMed Web of Science ®Google Scholar
• Mita T, Watada H, Shimizu T, Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control. Arterioscler Thromb Vasc Biol 2007;27:2456-62
   PubMed Web of Science ®Google Scholar
• Derosa G, D'Angelo A, Fogari E, Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. Intern Med 2007;46:1837-46
   PubMed Web of Science ®Google Scholar
• Raz I, Wilson PW, Strojek K, Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32:381-6
   PubMed Web of Science ®Google Scholar
• Woerle HJ, Neumann C, Zschau S, Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes: importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 2007;77:280-5
   PubMed Web of Science ®Google Scholar
• Holman RR, Farmer AJ, Davies MJ, Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736-47
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2010. Diabetes Care 2010;33( Suppl 1):S11-61
   PubMed Web of Science ®Google Scholar
• Guideline for management of postmeal glucose. Brussels, Belgium: International Diabetes Federation, 2007. Available from: http://www.idf.org/webdata/docs/Guideline_PMG_final.pdf. [Last accessed 7 January 2011]
   Google Scholar
• Rodbard HW, Blonde L, Braithwaite S, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13( Suppl 1):1-68
   PubMedGoogle Scholar
• Bolen S, Feldman L, Vassy J, Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-99
   PubMed Web of Science ®Google Scholar
• Moretto TJ, Milton DR, Ridge TD, Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008;30:1448-60
   PubMed Web of Science ®Google Scholar
• White J. Efficacy and safety of incretin-based therapies: clinical trial data. J Am Pharm Assoc 2009;49( Suppl 1):S30-40
   Google Scholar
• Raz I, Hanefeld M, Xu L, Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-71
   PubMed Web of Science ®Google Scholar
• Aschner PJ. The role for saxagliptin within the management of type 2 diabetes mellitus: an update from the 2010 European Association for the Study of Diabetes (EASD) 46th annual meeting and the American Diabetes Association (ADA) 70th scientific session. Diabetol Metab Syndr 2010;2:69
   PubMed Web of Science ®Google Scholar
• Van de Laar FA, Lucassen PL, Akkermans RP, Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;18:CD003639
   Google Scholar
• Buse JB, Weyer C, Maggs DG. Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. Clin Diabetes 2002;20:137-44
   Google Scholar
• Thomaseth K, Pacini G, Clodi M. Amylin release during oral glucose tolerance test. Diabet Med 1997;14( Suppl 2):S29-34
   PubMed Web of Science ®Google Scholar
• Juhl CB, Porksen N, Sturis J, High-frequency oscillations in circulating amylin concentrations in healthy humans. Am J Physiol Endocrinol Metab 2000;278:E484-90
   PubMed Web of Science ®Google Scholar
• Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 2004;53:S233-8
   PubMed Web of Science ®Google Scholar
• Ludvik B, Lell B, Hartter E, Decrease of stimulated amylin release precedes impairment of insulin secretion in type 2 diabetes. Diabetes 1991;40:1615-19
   PubMed Web of Science ®Google Scholar
• Roth JD, Maier H, Chen S, Roland BL. Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications. Arch Neurol 2009;66:306-10
   PubMedGoogle Scholar
• Young A. Receptor pharmacology. Adv Pharmacol 2005;52:47-65
   PubMedGoogle Scholar
• Young A. Inhibition of gastric emptying. Adv Pharmacol 2005;52:99-121
   PubMedGoogle Scholar
• Silvestre RA, Rodriguez-Gallardo J, Jodka C, Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Am J Physiol Endocrinol Metab 2001;280:E443-9
   Web of Science ®Google Scholar
• Gedulin BR, Jodka CM, Herrmann K, Young AA. Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187. Regul Pept 2006;137:121-7
   PubMedGoogle Scholar
• Abedini A, Singh G, Raleigh DP. Recovery and purification of highly-aggregation prone disulfide-containing peptides: application to islet amyloid polypeptide. Anal Biochem 2006;351:181-6
   PubMed Web of Science ®Google Scholar
• Young AA, Vine W, Gedulin BR, Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin. Drug Dev Res 1996;37:231-48
   Web of Science ®Google Scholar
• SYMLINA® (pramlintide acetate) injection. San Diego, CA: Amylin Pharmaceuticals, Inc., 2010. Available from: http://documents.symlin.com/SYMLIN_PI.pdf. [Last accessed 17 January 2011]
   Google Scholar
• Colburn WA, Gottlieb AB, Koda J, Kolterman OG. Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes. J Clin Pharmacol 1996;36:13-24
   PubMed Web of Science ®Google Scholar
• Weyer C, Gottlieb A, Kim DD, Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care 2003;26:3074-9
   PubMed Web of Science ®Google Scholar
• Maggs DG, Fineman M, Kornstein J, Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev 2004;20:55-60
   PubMed Web of Science ®Google Scholar
• Kolterman OG, Schwartz S, Corder C, Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 1996;39:492-9
   PubMed Web of Science ®Google Scholar
• Whitehouse F, Kruger DF, Fineman M, A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002;4:724-30
   Google Scholar
• Riddle M, Frias J, Zhang B, Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care 2007;11:2794-9
   Google Scholar
• Fineman MS, Koda JE, Shen LZ, The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 2002;51:636-41
   PubMed Web of Science ®Google Scholar
• Nyholm B, Orskov L, Hove KY, The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism 1999;48:935-41
   PubMed Web of Science ®Google Scholar
• Fineman M, Weyer C, Maggs DG, The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res 2002;34:504-8
   PubMed Web of Science ®Google Scholar
• Vella A, Lee JS, Camilleri M, Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol Motil 2002;14:123-31
   PubMed Web of Science ®Google Scholar
• Barnett JL, Owyang C. Serum glucose concentration as a modulator of interdigestive gastric motility. Gastroenterology 1988;94:739-44
   PubMed Web of Science ®Google Scholar
• Fraser RJ, Horowitz M, Maddox AF, Hyperglycemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990;33:675-80
   PubMed Web of Science ®Google Scholar
• Horowitz M, Harding PE, Maddox AF, Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989;32:151-9
   PubMed Web of Science ®Google Scholar
• Kong M-F, King P, Macdonald IA, Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia 1997;40:82-8
   PubMed Web of Science ®Google Scholar
• Chapman I, Parker B, Doran S, Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005;48:838-48
   PubMed Web of Science ®Google Scholar
• Heise T, Heinemann L, Heller S, Effect of pramlintide on symptom, catecholamine and glucagon responses to hypoglycemia in healthy subjects. Metabolism 2004;53:1227-32
   PubMed Web of Science ®Google Scholar
• Schvarcz E, Palmer M, Aman J, Berne C. Hypoglycemia increases the gastric emptying rate in healthy subjects. Diabetes Care 1995;18:674-6
   PubMed Web of Science ®Google Scholar
• Russo A, Stevens JE, Chen R, Insulin-induced hypoglycemia accelerates gastric emptying of solids and liquids in long-standing type 1 diabetes. J Clin Endocrinol Metab 2005;90:4489-95
   PubMed Web of Science ®Google Scholar
• Schvarcz E, Palmer M, Aman J, Hypoglycemia increases the gastric emptying rate in patients with type 1 diabetes mellitus. Diabet Med 1993;10:660-3
   PubMed Web of Science ®Google Scholar
• Gedulin BR, Young AA. Hypoglycemia overrides amylin-mediated regulation of gastric emptying in rats. Diabetes 1998;47:93-7
   PubMed Web of Science ®Google Scholar
• Amiel SA, Heller SR, Macdonald IA, The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes. Diabetes Obes Metab 2005;7:504-16
   PubMed Web of Science ®Google Scholar
• Moyses C, Kolterman O, Mant T. Pharmacokinetics and hyperglycaemic effects of the amylin analogue, AC137, in man [abstract]. Diabet Med 1993;10:S25
   Google Scholar
• Moyses C, Kolterman O, Nuttall A, First administration to man of the human amylin analogue tripro-amylin [abstract]. Diabetologia 1994;37( Suppl 1):72
   Google Scholar
• Young A. Tissue expression and secretion of amylin. Adv Pharmacol 2005;52:19-37
   PubMedGoogle Scholar
• Young A. Clinical studies. Adv Pharmacol 2005;52:289-320
   PubMedGoogle Scholar
• Weyer C, Fineman MS, Strobel S, Properties of pramlintide and insulin upon mixing. Am J Health Syst Pharm 2005;62:816-22
   PubMed Web of Science ®Google Scholar
• Want LL, Ratner RE. Pramlintide: a new tool in diabetes management. Curr Diab Rep 2006;6:344-9
   PubMedGoogle Scholar
• Want LL. Optimizing treatment success with an amylin analogue. Diabetes Educ 2008;34:11S-17S
   Web of Science ®Google Scholar
• King AB. Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is established and square-wave meal bolus is used. Endocr Pract 2009;15:229-33
   PubMed Web of Science ®Google Scholar
• King AB. Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated type 1 diabetes patients. Diabetes Technol Ther 2010;12:105-8
   PubMed Web of Science ®Google Scholar
• Kellmeyer TA, Kesty NC, Wang Y, Pharmacokinetics of an oral drug (acetaminophen) administered at various times relative to subcutaneous injection of pramlintide in subjects with type 2 diabetes. J Clin Pharmacol 2007;47:798-805
   PubMed Web of Science ®Google Scholar
• Neumiller JJ, Setter SM. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother 2009;7:324-42
   PubMed Web of Science ®Google Scholar
• Ratner RE, Dickey R, Fineman M, Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year randomized controlled trial. Diabet Med 2004;11:1204-12
   Google Scholar
• Edelman S, Garg S, Frias J, A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 2006;10:2189-95
   Google Scholar
• Hollander PA, Levy P, Fineman MS, Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003;3:784-90
   Google Scholar
• Riddle M, Pencek R, Charenkavanich S, Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care 2009;32:1577-82
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR, Polonsky WH, Best JH. Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs. Curr Med Res Opin 2010;26:1047-54
   PubMed Web of Science ®Google Scholar
• Wild D, von Maltzahn R, Brohan E, A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns 2007;68:10-15
   PubMed Web of Science ®Google Scholar
• VanDeKoppel S, Choe HM, Sweet BV. Managed care perspective on three new agents for type 2 diabetes. J Manag Care Pharm 2008;14:363-80
   PubMed Web of Science ®Google Scholar
• Heptulla RA, Rodriguez LM, Bomgaars L, Haymond MW. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes 2005;54:1100-7
   PubMed Web of Science ®Google Scholar
• Rodriguez LM, Mason KJ, Haymond MW, Heptulla RA. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes. Pediatr Res 2007;62:746-9
   PubMed Web of Science ®Google Scholar
• Chase HP, Lutz K, Pencek R, Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. J Pediatr 2009;155:369-73
   PubMed Web of Science ®Google Scholar
• Hassan K, Heptulla RA. Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus. Pediatr Diabetes 2009;10:264-8
   PubMed Web of Science ®Google Scholar
• Huffman DM, McLean GW, Seagrove MA. Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study. Endocr Pract 2009;15:689-95
   PubMed Web of Science ®Google Scholar
• Smith SR, Aronne LJ, Burns CM, Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008;31:1816-23
   PubMed Web of Science ®Google Scholar
• Aronne L, Fujioka K, Aroda V, Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab 2007;8:2977-83
   Google Scholar
• Roth JD, Roland BL, Cole RL, Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA 2008;105:7257-62
   PubMed Web of Science ®Google Scholar
• Ravussin E, Smith SR, Mitchell JA, Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009;17:1736-43
   PubMed Web of Science ®Google Scholar
• Pramlintide/ Metreleptin. San Diego, CA: Amylin Pharmaceuticals, Inc., 2010. Available from: http://www.amylin.com/research/pipeline/pramlintide–metreleptin.htm. [Last accessed 17 January 2011]
   Google Scholar
• Amylin and takeda announce decision to advance development of pramlintide/metreleptin combination treatment for obesity: phase 2 extension study demonstrated sustained weight loss. Osaka, Japan: Takeda Pharmaceutical Company Limited, 2010. Available from: http://www.takeda.com/press/article_35851.html. [Last accessed 04 April 2011]
   Google Scholar
• Amylin and Takeda voluntarily suspend clinical activities in obesity trial. Osaka, Japan: Takeda Pharmaceutical Company Limited, 2011. Available from: http://www.takeda.com/press/article_40299.html. [Last accessed 04 April 2011]
   Google Scholar